Johnson Matthey (LON:JMAT - Get Free Report) had its price target increased by analysts at Deutsche Bank Aktiengesellschaft from GBX 2,100 to GBX 2,300 in a research note issued on Thursday,London Stock Exchange reports. The firm currently has a "buy" rating on the stock. Deutsche Bank Aktiengesellschaft's price objective would suggest a potential upside of 11.18% from the company's current price.
Separately, Berenberg Bank lifted their price objective on shares of Johnson Matthey from GBX 1,950 to GBX 2,100 and gave the company a "hold" rating in a research report on Thursday. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of GBX 2,066.67.
View Our Latest Analysis on Johnson Matthey
Johnson Matthey Price Performance
Shares of Johnson Matthey stock traded up GBX 0.74 on Thursday, hitting GBX 2,068.74. 322,726 shares of the company traded hands, compared to its average volume of 1,804,208. The stock has a market capitalization of £3.47 billion, a P/E ratio of 979.52, a price-to-earnings-growth ratio of 49,242.50 and a beta of 0.95. The company has a debt-to-equity ratio of 62.73, a quick ratio of 0.76 and a current ratio of 1.45. Johnson Matthey has a 52 week low of GBX 1,131 and a 52 week high of GBX 2,112. The business has a 50-day simple moving average of GBX 1,906.01 and a 200 day simple moving average of GBX 1,668.91.
Insider Buying and Selling
In other news, insider Andrew Cosslett acquired 10,495 shares of the company's stock in a transaction on Tuesday, August 26th. The stock was bought at an average cost of GBX 1,896 per share, with a total value of £198,985.20. 0.50% of the stock is owned by insiders.
Johnson Matthey Company Profile
(
Get Free Report)
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers' products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet's natural resources.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson Matthey, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson Matthey wasn't on the list.
While Johnson Matthey currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.